Claims

1. Use of paliperidone palmitate in the manufacture of a medicament for the treatment of psychosis, schizophrenia, schizoaffective disorder, schizophreniform disorder, or bipolar disorder in a patient in need thereof who has been administered a first dose of a first paliperidone palmitate extended-release injectable suspension having a six month dosing interval ("PP6M") (first suspension), wherein the use comprises:

a re-initiation loading dose of a second paliperidone palmitate extended-release injectable suspension having a one month dosing interval ("PP1M") (second suspension) to be administered in a deltoid muscle of the patient at a time that is more than six months and three weeks after administration of said first dose of the first suspension but less than eight months after administration of said first dose of the first suspension; and

a maintenance dose of the first suspension to be administered in the deltoid or gluteal muscle of the patient at a time that is about one month (± 7 days) after administration of the re-initiation loading dose of the second suspension,

wherein there are no intervening doses of paliperidone palmitate between the first dose and the re-initiation loading dose,

wherein the PP6M (first suspension) comprises about 312 mg/mL of paliperidone palmitate;

wherein the PP1M (second suspension) comprises about 156 mg/mL of paliperidone palmitate;

wherein the paliperidone palmitate extended-release injectable suspensions are aqueous compositions further comprising a suspending agent, a buffer, and optionally one or more of a preservative and an isotonizing agent, and

wherein either

(i) the first dose of the first suspension comprises about 1092 mg of paliperidone palmitate; the re-initiation loading dose of the second suspension comprises about 156 mg of paliperidone palmitate; and the maintenance dose of the first suspension comprises about 1092 mg of paliperidone palmitate, or

(ii) the first dose of the first suspension comprises about 1560 mg of paliperidone palmitate; the re-initiation loading dose of the second suspension comprises about 234

mg of paliperidone palmitate; and the maintenance dose of the first suspension comprises about 1560 mg of paliperidone palmitate.

2. The use of claim 1, wherein the first dose of the first suspension comprises about 1092 mg of paliperidone palmitate; the re-initiation loading dose of the second suspension comprises about 156 mg of paliperidone palmitate; and the maintenance dose of the first suspension comprises about 1092 mg of paliperidone palmitate.

3. The use of claim 1, wherein the first dose of the first suspension comprises about 1560 mg of paliperidone palmitate; the re-initiation loading dose of the second suspension comprises about 234 mg of paliperidone palmitate; and the maintenance dose of the first suspension comprises about 1560 mg of paliperidone palmitate.

4. Use of paliperidone palmitate in a manufacture of a medicament for the treatment of psychosis, schizophrenia, schizoaffective disorder, schizophreniform disorder, or bipolar disorder in a patient in need thereof who has been administered a first dose of a first paliperidone palmitate extended-release injectable suspension having a six month dosing interval ("PP6M") (first suspension), wherein the use comprises:

a first re-initiation loading dose of about 156 mg paliperidone palmitate of a second paliperidone palmitate extended-release injectable suspension having a one month dosing interval ("PP1M") (second suspension) to be administered to the deltoid muscle of the patient at a time that is from 8 months up to and including 11 months after administration of the first dose of the first suspension;

a second re-initiation loading dose of about 156 mg paliperidone palmitate of the second suspension to be administered in the deltoid muscle of the patient on about day 8 (± 4 days) after administration of the first re-initiation loading dose of the second suspension; and

a maintenance dose of the first suspension to be administered in the deltoid or gluteal muscle of the patient about 1 month (±7 days) after administration of the second re-initiation loading dose of the second suspension,

wherein there are no intervening doses of paliperidone palmitate between the first dose and the first re-initiation loading dose,

wherein the PP6M (first suspension) comprises about 312 mg/mL of paliperidone palmitate;

wherein the PP1M (second suspension) comprises about 156 mg/mL of paliperidone palmitate;

wherein the paliperidone palmitate extended-release injectable suspensions are aqueous compositions further comprising a suspending agent, a buffer, and optionally one or more of a preservative and an isotonizing agent, and

wherein either

(i) the first dose of the first suspension comprises about 1092 mg paliperidone palmitate and the maintenance dose of the first suspension comprises about 1092 mg paliperidone palmitate, or

(ii) the first dose of the first suspension comprises about 1560 mg paliperidone palmitate and the maintenance dose of the first suspension comprises about 1560 mg paliperidone palmitate.

5. The use of claim 4, wherein the first dose of the first suspension comprises about 1092 mg paliperidone palmitate and the maintenance dose of the first suspension comprises about 1092 mg paliperidone palmitate.

6. The use of claim 4, wherein the first dose of the first suspension comprises about 1560 mg paliperidone palmitate and the maintenance dose of the first suspension comprises about 1560 mg paliperidone palmitate.

7. Use of paliperidone palmitate in a manufacture of a medicament for the treatment of psychosis, schizophrenia, schizoaffective disorder, schizophreniform disorder, or bipolar disorder in a patient in need thereof who has been administered a first dose of a first paliperidone palmitate extended-release injectable suspension having a six month dosing interval ("PP6M") (first suspension), wherein the use comprises:

(1) a first re-initiation loading dose of about 234 mg paliperidone palmitate of a second paliperidone palmitate extended-release injectable suspension having a one month dosing

interval ("PP1M") (second suspension) to be administered in the deltoid muscle of the patient at a time that is more than 11 months after administration of the first dose of the first suspension;

(2) a second re-initiation loading dose of about 156 mg paliperidone palmitate of the second suspension to be administered in the deltoid muscle of the patient on about day 8 (± 4 days) after administration of the first re-initiation loading dose of the second suspension;

(3) a first re-initiation maintenance dose of about 39 mg to about 234 mg paliperidone palmitate of the second suspension to be administered in the deltoid or gluteal muscle of the patient about 1 month (±7 days) after administration of the second re-initiation loading dose of the second suspension;

(4) a second re-initiation maintenance dose of from about 39 mg to about 234 mg paliperidone palmitate of the second suspension to be administered in the deltoid or gluteal muscle of the patient about 1 month (±7 days) after administration of the first re-initiation maintenance dose of the second suspension;

(5) a third re-initiation maintenance dose of from about 39 mg to about 234 mg paliperidone palmitate of the second suspension to be administrated in the deltoid or gluteal muscle of the patient about 1 month (±7 days) after administration of the second re-initiation maintenance dose of the second suspension; and

(6) a maintenance dose of the first suspension to be administered in the deltoid or gluteal muscle of the patient about 1 month (±7 days) after administration of the third re-initiation maintenance dose of the second suspension,

wherein there are no intervening doses of paliperidone palmitate between the first dose and the first re-initiation loading dose,

wherein the PP6M (first suspension) comprises about 312 mg/mL of paliperidone palmitate;

wherein the PP1M (second suspension) comprises about 156 mg/mL of paliperidone palmitate;

wherein the paliperidone palmitate extended-release injectable suspensions are aqueous compositions further comprising a suspending agent, a buffer, and optionally one or more of a preservative and an isotonizing agent, and

wherein either

(i) the first dose of the first suspension comprises about 1092 mg paliperidone palmitate and the maintenance dose of the first suspension comprises about 1092 mg paliperidone palmitate, or

(ii) the first dose of the first suspension comprises about 1560 mg paliperidone palmitate and the maintenance dose of the first suspension comprises about 1560 mg paliperidone palmitate.

8. The use of claim 7, wherein the first dose of the first suspension comprises about 1092 mg paliperidone palmitate and the maintenance dose of the first suspension comprises about 1092 mg paliperidone palmitate.

9. The use of claim 7, wherein the first dose of the first suspension comprises about 1560 mg paliperidone palmitate and the maintenance dose of the first suspension comprises about 1560 mg paliperidone palmitate.

10. The use of any one of the preceding claims wherein the first dose of the first suspension and the maintenance dose of the first suspension is to be administered in the gluteal muscle.

11. The use of any one of the preceding claims, wherein the patient is in need of treatment for schizophrenia.

12. The use of any one of the preceding claims, wherein the first suspension comprises:
about 312 mg/mL of the paliperidone palmitate;
8 mg/mL to 12 mg/mL of a wetting agent;
one or more buffering agents;
65 mg/mL to 85 mg/mL of a suspending agent; and
water q.s. ad 100%.

13. The use of claim 12, wherein the first suspension is from pH 6.0 to pH 8.0.

14. The use of claim 12 or claim 13, wherein the one or more buffering agents comprise citric acid monohydrate, sodium dihydrogen phosphate monohydrate, disodium hydrogen phosphate anhydrous, or sodium hydroxide.

15. The use of claim 12, wherein the first suspension comprises:
about 312 mg/mL of paliperidone palmitate;
about 10 mg/mL of polysorbate 20; and
about 75 mg/mL of polyethylene glycol 4000.

16. The use of any one of the preceding claims, wherein the second suspension comprises:
about 156 mg/ml of the paliperidone palmitate;
8 mg/mL to 16 mg/ml of a wetting agent;
one or more buffering agents;
20 mg/mL to 40 mg/ml of a suspending agent; and
water q.s. ad 100%.

17. The use of claim 16, wherein the second suspension is from pH 6.0 to pH 8.0.

18. The use of claim 16 or claim 17, wherein the one or more buffering agents comprise citric acid monohydrate, sodium dihydrogen phosphate monohydrate, disodium hydrogen phosphate anhydrous, or sodium hydroxide.

19. The use of claim 16, wherein the second suspension comprises:
about 156 mg/mL of paliperidone palmitate;
about 12 mg/mL of polysorbate 20; and
about 30 mg/mL of polyethylene glycol 4000.

20. The use according to any one of the preceding claims, wherein said patient in need thereof who has been administered a first dose of a paliperidone palmitate extended-release injectable suspension having a six month dosing interval (PP6M) (first suspension) has also been administered a paliperidone palmitate extended-release injectable suspension having either a

one-month dosing interval (PP1M) or a three-month dosing interval (PP3M) prior to administration of said first dose of said first suspension.

21. The use according to claim 20, wherein said patient in need thereof has been administered said PP1M for at least four months or said PP3M for at least one 3-month interval prior to administration of said first dose of said first suspension.

22. The use according to claim 20 or claim 21, wherein:

(a) the dose of said PP1M that has been administered to said patient prior to administration of said first dose of said first suspension was about 156 mg or about 234 mg paliperidone palmitate; or

(b) the dose of said PP3M that has been administered to said patient prior to administration of said first dose of said first suspension was about 546 mg or about 819 mg paliperidone palmitate.

23. The use according to claim 21 or claim 22, wherein:

(a) said patient has been administered PP1M for at least four months prior to administration of said first dose of said first suspension, and said first dose of said first suspension has been administered 1 month ± 7 days after the last dose of said PP1M has been administered; and/or

(b) (i) if the last dose of said PP1M that has been administered prior to administration of said first dose of said first suspension was about 156 mg paliperidone palmitate, said first dose of said first suspension was about 1092 mg paliperidone palmitate; or

(ii) if the last dose of said PP1M that has been administered prior to administration of said first dose of said first suspension was about 234 mg paliperidone palmitate, said first dose of said first suspension was about 1560 mg paliperidone palmitate.

24. The use according to claim 21 or claim 22, wherein:

(a) said patient has been administered PP3M for at least one 3-month interval prior to administration of said first dose of said first suspension, and said first dose of said first suspension has been administered 3 months ± 14 days after the last dose of said PP3M has been administered; and/or

(b) (i) if the last dose of said PP3M that has been administered prior to administration of said first dose of said first suspension was about 546 mg paliperidone palmitate, said first dose of the first suspension was about 1092 mg paliperidone palmitate; or

(ii) if the last dose of said PP3M that has been administered prior to administration of said first dose of said first suspension was about 819 mg paliperidone palmitate, said first dose of the first suspension was about 1560 mg paliperidone palmitate.

25. The use according to any of the preceding claims, wherein said first suspension is in a pre-filled syringe having a tip cap and a thin-walled 20 gauge 1.5 inch needle, and optionally wherein the syringe is shaken with the tip cap pointing up for at least 15 seconds, and after a rest, the syringe is shaken again for another 15 seconds before administration of said first suspension.

26. The use according to any one of claims 20-23 or 25, wherein said PP1M that has been administered prior to administration of said first dose of said first suspension comprises:

140 mg/mL to 180 mg/mL of paliperidone palmitate;
8 mg/mL to 16 mg/mL of a wetting agent;
5 mg/mL to 15 mg/mL of one or more buffering agents;
20 mg/mL to 40 mg/mL of a suspending agent; and
water q.s. ad 100%,

optionally wherein said PP1M that has been administered prior to administration of said first dose of said first suspension comprises:

about 156 mg/mL of paliperidone palmitate;
about 12 mg/mL of polysorbate 20;
about 30 mg/mL of polyethylene glycol 4000;
about 5 mg/mL citric acid monohydrate;

about 2.5 mg/mL sodium dihydrogen phosphate monohydrate;
about 5 mg/mL disodium hydrogen phosphate anhydrous;
about 2.84 mg/mL sodium hydroxide; and
water for injection.

27. The use according to any one of claims 20-22, 24 or 25, wherein said PP3M that has been administered prior to administration of said first dose of said first suspension comprises:

280 mg/mL to 350 mg/mL of paliperidone palmitate;
8 mg/mL to 12 mg/mL of a wetting agent;
5 to 15 mg/mL of one or more buffering agents;
65 mg/mL to 85 mg/mL of a suspending agent; and
water q.s. ad 100%,

optionally wherein said PP3M that has been administered prior to administration of said first dose of said first suspension comprises:

about 312 mg/mL of paliperidone palmitate;
about 10 mg/mL of polysorbate 20;
about 75 mg/mL of polyethylene glycol 4000;
about 7.5 mg/mL citric acid monohydrate;
about 6 mg/mL sodium dihydrogen phosphate monohydrate;
about 5.4 mg/mL sodium hydroxide; and
water for injection.